|
RU2015102845A
(ru)
*
|
2010-02-23 |
2015-06-10 |
Санофи |
АНТИТЕЛА К ИНТЕГРИНУ α2 И ИХ ПРИМЕНЕНИЯ
|
|
UY33578A
(es)
|
2010-08-31 |
2012-03-30 |
Sanofi Sa |
PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
|
|
PH12013501201A1
(en)
*
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
US9605320B2
(en)
*
|
2011-01-13 |
2017-03-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of predicting responsiveness of B cell lineage malignancies to active immunotherapy
|
|
EA201791693A1
(ru)
|
2011-03-25 |
2018-05-31 |
Гленмарк Фармасьютикалс С.А. |
Гетеродимерные иммуноглобулины
|
|
PH12014500089A1
(en)
|
2011-07-11 |
2014-02-17 |
Ichnos Sciences SA |
Antibodies that bind to ox40 and their uses
|
|
PL2744826T3
(pl)
|
2011-08-16 |
2022-05-30 |
Morphosys Ag |
Terapia skojarzona przeciwciałem anty-cd19 i analogiem puryny
|
|
KR20200058583A
(ko)
|
2011-08-16 |
2020-05-27 |
모르포시스 아게 |
항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
|
|
JP2015529236A
(ja)
|
2012-09-25 |
2015-10-05 |
グレンマーク ファーマシューティカルズ， エセ．アー． |
ヘテロ二量体免疫グロブリンの精製
|
|
SMT201800346T1
(it)
|
2012-10-12 |
2018-09-13 |
Medimmune Ltd |
Coniugati pirrolobenzodiazepina-anticorpo
|
|
PT2906298T
(pt)
|
2012-10-12 |
2018-12-28 |
Medimmune Ltd |
Conjugados de pirrolobenzodiazepina-anticorpos
|
|
WO2014057074A1
(en)
|
2012-10-12 |
2014-04-17 |
Spirogen Sàrl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
JP2016503818A
(ja)
|
2013-01-02 |
2016-02-08 |
グレンマーク ファーマシューティカルズ， エセ．アー． |
Ｔｌ１ａと結合する抗体およびその使用
|
|
CA2907397C
(en)
|
2013-03-15 |
2022-11-22 |
Anthrogenesis Corporation |
Modified t lymphocytes
|
|
UY35468A
(es)
*
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
US10150814B2
(en)
|
2013-06-27 |
2018-12-11 |
Abbvie Biotherapeutics Inc. |
Fc variants with improved complement activation
|
|
EP3054985B1
(en)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
NZ758715A
(en)
*
|
2013-10-31 |
2023-01-27 |
Seattle Children’S Hospital Dba Seattle Children’S Res Institute |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
|
JP2016538275A
(ja)
|
2013-11-04 |
2016-12-08 |
グレンマーク ファーマシューティカルズ， エセ．アー． |
Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
|
|
US10640569B2
(en)
|
2013-12-19 |
2020-05-05 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
LT3129470T
(lt)
|
2014-04-07 |
2021-07-12 |
Novartis Ag |
Vėžio gydymas naudojant anti-cd19 chimerinį antigeno receptorių
|
|
US11041021B2
(en)
|
2014-05-23 |
2021-06-22 |
University Of Florida Research Foundation, Incorporated |
Car based immunotherapy
|
|
JP7054622B2
(ja)
|
2014-07-21 |
2022-04-14 |
ノバルティス アーゲー |
ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
|
|
TWI751102B
(zh)
*
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對ｃｄ１９具專一性之抗體及嵌合抗原受體
|
|
EP2990416B1
(en)
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
WO2016061368A1
(en)
*
|
2014-10-15 |
2016-04-21 |
The Children's Hospital Of Philadelphia |
Compositions and methods for treating b-lymphoid malignancies
|
|
MA41480A
(fr)
|
2014-10-17 |
2017-12-19 |
Glenmark Pharmaceuticals Sa |
Anticorps qui se lient au ccr6 et leurs utilisations
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
KR102804498B1
(ko)
|
2014-12-03 |
2025-05-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료를 위한 방법 및 조성물
|
|
US12428483B2
(en)
*
|
2014-12-22 |
2025-09-30 |
Systimmune, Inc. |
Bispecific tetravalent antibodies and methods of making and using thereof
|
|
US11248058B2
(en)
*
|
2015-02-19 |
2022-02-15 |
University Of Florida Research Foundation, Inc. |
Chimeric antigen receptors and uses thereof
|
|
GB201503742D0
(en)
*
|
2015-03-05 |
2015-04-22 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
HRP20220893T1
(hr)
|
2015-04-08 |
2022-10-14 |
Novartis Ag |
Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
|
|
WO2016168769A1
(en)
*
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Chimeric receptor t cell switches for her2
|
|
WO2016176651A2
(en)
*
|
2015-04-29 |
2016-11-03 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
|
EP3466967A1
(en)
|
2015-05-18 |
2019-04-10 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
HUE046328T2
(hu)
|
2015-05-26 |
2020-03-30 |
Morphosys Ag |
CD19 elleni ellenanyag és Bruton-féle tirozin-kináz gátlójának kombinációja és a kombináció alkalmazásai
|
|
WO2017015783A1
(en)
*
|
2015-07-24 |
2017-02-02 |
Shanghai Sidansai Biotechnology Co., Ltd |
Humanized anti-cd19 antibody and use thereof
|
|
US10493139B2
(en)
|
2015-07-24 |
2019-12-03 |
Innovative Cellular Therapeutics CO., LTD. |
Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
|
|
AU2016311136B2
(en)
|
2015-08-21 |
2022-02-17 |
Incyte Corporation |
Combinations and uses thereof
|
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
|
AR106188A1
(es)
*
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
EP3356407B1
(en)
*
|
2015-10-02 |
2021-11-03 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
MX2018006789A
(es)
|
2015-12-03 |
2019-02-13 |
Juno Therapeutics Inc |
Receptores quimericos modificados y composiciones y metodos relacionados.
|
|
EP3383419B1
(en)
*
|
2015-12-03 |
2022-08-03 |
Juno Therapeutics, Inc. |
Compositions and methods for reducing immune responses against chimeric antigen receptors
|
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
PT3916392T
(pt)
|
2016-05-30 |
2024-06-04 |
Incyte Corp |
Métodos para prever o benefício terapêutico da terapia anti-cd19 nos pacientes
|
|
HRP20210945T1
(hr)
|
2016-06-27 |
2021-09-17 |
Morphosys Ag |
Formulacije protutijela anti-cd19
|
|
AU2017341047B2
(en)
|
2016-10-07 |
2024-10-10 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
EP4092049A1
(en)
|
2016-10-20 |
2022-11-23 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
|
LT3532098T
(lt)
|
2016-10-28 |
2021-06-25 |
Morphosys Ag |
Anti cd19 antikūno derinys su bcl-2 inhibitoriumi, ir jo naudojimas
|
|
CA3044593A1
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
AU2017366739B2
(en)
|
2016-12-02 |
2023-11-23 |
Angeles Therapeutics, Inc. |
Synthetic immune receptors and methods of use thereof
|
|
EP3609536B1
(en)
*
|
2017-01-05 |
2022-03-09 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
ES2871001T3
(es)
|
2017-02-08 |
2021-10-28 |
Adc Therapeutics Sa |
Conjugados de pirrolobenzodiazepinas y anticuerpos
|
|
CN106967171B
(zh)
*
|
2017-02-23 |
2021-04-27 |
郑州大学 |
一种全人源重组CD40L单抗Fab片段及其制备方法
|
|
WO2018192944A1
(en)
|
2017-04-18 |
2018-10-25 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
|
JP2020517259A
(ja)
|
2017-04-19 |
2020-06-18 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
操作された抗原受容体を発現する免疫細胞
|
|
JOP20180042A1
(ar)
*
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
|
MX421249B
(es)
|
2017-05-10 |
2025-02-10 |
Wistar Inst |
Constructos de anticuerpos de ácidos nucleicos optimizados
|
|
WO2018220040A1
(en)
|
2017-05-31 |
2018-12-06 |
Morphosys Ag |
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
|
|
ES2988683T3
(es)
|
2017-06-14 |
2024-11-21 |
Adc Therapeutics Sa |
Pautas posológicas para la administración de un CAF anti-CD19
|
|
JP7279011B2
(ja)
|
2017-07-10 |
2023-05-22 |
インターナショナル－ドラッグ－ディベロップメント－バイオテック |
抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療
|
|
US11447546B2
(en)
*
|
2017-07-20 |
2022-09-20 |
Nbe-Therapeutics Ag |
Human antibodies binding to ROR2
|
|
SG11202000358YA
(en)
|
2017-08-18 |
2020-02-27 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
SG11202001817PA
(en)
*
|
2017-09-21 |
2020-03-30 |
Wuxi Biologics Ireland Ltd |
Novel anti-cd19 antibodies
|
|
SG11202003879RA
(en)
|
2017-10-30 |
2020-05-28 |
Neuropore Therapies Inc |
Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
|
|
AU2018379502B2
(en)
*
|
2017-12-06 |
2025-07-17 |
Abclon Inc. |
Antibody or antigen binding fragment thereof for specifically recognizing B cell malignancy, chimeric antigen receptor comprising same, and use thereof
|
|
JP7080514B2
(ja)
|
2017-12-22 |
2022-06-06 |
アブクロン・インコーポレイテッド |
悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途
|
|
CN109053899B
(zh)
*
|
2017-12-22 |
2021-11-16 |
湖南远泰生物技术有限公司 |
一种含人转铁蛋白抗原表位序列的嵌合体抗原受体
|
|
CN108047332B
(zh)
*
|
2018-01-15 |
2021-08-24 |
阿思科力(苏州)生物科技有限公司 |
以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
|
|
JP7273421B2
(ja)
|
2018-02-21 |
2023-05-15 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
KR20200030337A
(ko)
|
2018-09-12 |
2020-03-20 |
주식회사 녹십자랩셀 |
종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
|
|
CN109293774B
(zh)
*
|
2018-10-16 |
2021-05-28 |
南京医科大学 |
特异性结合cd19的全人源化抗体及应用
|
|
CN116726361A
(zh)
|
2018-11-19 |
2023-09-12 |
比奥拉治疗股份有限公司 |
用生物治疗剂治疗疾病的方法和装置
|
|
CN113412117B
(zh)
|
2018-12-12 |
2025-03-04 |
凯德药业股份有限公司 |
嵌合抗原和t细胞受体及使用的方法
|
|
MX2021007307A
(es)
|
2018-12-21 |
2021-07-07 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3.
|
|
JP7090780B2
(ja)
*
|
2018-12-21 |
2022-06-24 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｄ３に結合する抗体
|
|
CN118546959A
(zh)
*
|
2019-03-05 |
2024-08-27 |
恩卡尔塔公司 |
Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
|
|
MX2021010477A
(es)
|
2019-03-15 |
2021-10-01 |
Medimmune Ltd |
Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
|
|
AU2020270888A1
(en)
*
|
2019-04-08 |
2021-11-04 |
Memorial Sloan Kettering Cancer Center |
CD19 antibodies and methods of using the same
|
|
CN113939319A
(zh)
*
|
2019-04-30 |
2022-01-14 |
克里斯珀医疗股份公司 |
靶向cd19的基因工程化t细胞针对b细胞恶性肿瘤的同种异体细胞疗法
|
|
MA55794A
(fr)
|
2019-05-03 |
2022-03-09 |
Morphosys Ag |
Thérapie anti-cd19 chez des patients ayant un nombre limité de cellules nk
|
|
MX2022000016A
(es)
*
|
2019-06-27 |
2022-02-24 |
Crispr Therapeutics Ag |
Uso de linfocitos t con receptor de antigeno quimerico e inhibidores de linfocitos citoliticos naturales para el tratamiento del cancer.
|
|
WO2021004446A1
(en)
|
2019-07-09 |
2021-01-14 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing pseudomonas pcrv and uses thereof
|
|
CN110396129B
(zh)
*
|
2019-07-10 |
2020-11-24 |
武汉思安医疗技术有限公司 |
人源化cd19抗原结合单链抗体及其嵌合抗原受体、免疫细胞和应用
|
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
AU2020372646A1
(en)
|
2019-10-31 |
2022-05-12 |
Incyte Corporation |
Anti-tumor combination therapy comprising anti-CD19 antibody and gamma delta T-cells
|
|
KR20220103969A
(ko)
|
2019-10-31 |
2022-07-25 |
모르포시스 아게 |
백혈병 또는 림프종의 치료를 위해 레날리도마이드와 조합된 항-cd19 요법
|
|
EP4065158A2
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
US11707610B2
(en)
|
2019-12-13 |
2023-07-25 |
Biora Therapeutics, Inc. |
Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
|
|
EP4103620A1
(en)
*
|
2020-02-11 |
2022-12-21 |
Crispr Therapeutics AG |
Anti-idiotype antibodies targeting anti-cd19 chimeric antigen receptor
|
|
WO2021221783A1
(en)
*
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
PE20231080A1
(es)
|
2020-06-19 |
2023-07-17 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y cd19
|
|
JP2023530499A
(ja)
|
2020-06-22 |
2023-07-18 |
モルフォシス・アーゲー |
抗ＣＤ１９抗体及びＳＩＲＰα－ＣＤ４７自然免疫チェックポイントを遮断するポリペプチドを含む抗腫瘍組み合わせ療法
|
|
TW202229349A
(zh)
|
2020-10-06 |
2022-08-01 |
美商山可爾股份有限公司 |
用於治療包括全身性紅斑性狼瘡(sle)的自體免疫疾病之生物標記、方法及組合物
|
|
US20230406922A1
(en)
*
|
2020-11-20 |
2023-12-21 |
Simcere Zaiming Pharmaceutical Co., Ltd. |
Humanized cd19 antibody and use thereof
|
|
BR112023010885A2
(pt)
|
2020-12-04 |
2023-10-03 |
Incyte Corp |
Terapia de combinação de anti-cd19
|
|
US20240425563A1
(en)
*
|
2021-01-13 |
2024-12-26 |
Washington University |
MHC-INDEPENDENT TCRs AND METHODS OF MAKING AND USING SAME
|
|
CN112679612B
(zh)
*
|
2021-01-29 |
2022-07-01 |
武汉华美生物工程有限公司 |
抗cd19人源化抗体及其制备方法与应用
|
|
JP2024518410A
(ja)
*
|
2021-05-07 |
2024-05-01 |
ビエラ バイオ インコーポレイテッド |
重症筋無力症を治療するための抗ｃｄ１９抗体の使用
|
|
WO2023073645A1
(en)
|
2021-10-29 |
2023-05-04 |
Takeda Pharmaceutical Company Limited |
Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
|
|
US20250084169A1
(en)
|
2022-01-12 |
2025-03-13 |
Biomolecular Holdings Llc |
Nk/monocyte engagers
|
|
EP4572756A1
(en)
|
2022-08-17 |
2025-06-25 |
Incyte Corporation |
Therapy comprising anti-cd19 antibody and ezh2 modulators
|
|
AU2024264056A1
(en)
*
|
2023-04-28 |
2025-11-20 |
Shenzhen Shenxin Biotechnology Co., Ltd. |
Modified delivery vector and use thereof
|
|
WO2024251263A1
(en)
|
2023-06-09 |
2024-12-12 |
Jw Therapeutics R & D (Shanghai) Co., Ltd. |
Fusion protein and medical use thereof
|
|
US20250197501A1
(en)
*
|
2023-12-19 |
2025-06-19 |
Development Center For Biotechnology |
Recombinant antibody, immunoconjugate comprising the same, and uses thereof in treating cancers
|